291 related articles for article (PubMed ID: 37034092)
1. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
Overeem LH; Lange KS; Fitzek MP; Siebert A; Steinicke M; Triller P; Hong JB; Reuter U; Raffaelli B
Front Neurol; 2023; 14():1154420. PubMed ID: 37034092
[TBL] [Abstract][Full Text] [Related]
2. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
[TBL] [Abstract][Full Text] [Related]
3. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
4. Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine.
Youn MS; Kim N; Lee MJ; Kim M
J Clin Neurol; 2024 May; 20(3):300-305. PubMed ID: 38713076
[TBL] [Abstract][Full Text] [Related]
5. Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
Chase BA; Semenov I; Rubin S; Meyers S; Mark A; Makhlouf T; Chirayil TT; Maraganore D; Wei J; Zheng SL; Xu J; Epshteyn A; Pham A; Frigerio R; Markopoulou K
Headache; 2024 Jan; 64(1):68-92. PubMed ID: 38071464
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis.
Lambru G; Caponnetto V; Hill B; Ratti S; Sacco S; Murphy M; Briscoe J; Andreou AP
Neurotherapeutics; 2023 Sep; 20(5):1284-1293. PubMed ID: 37430146
[TBL] [Abstract][Full Text] [Related]
7. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
[TBL] [Abstract][Full Text] [Related]
8. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B
J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428
[TBL] [Abstract][Full Text] [Related]
9. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of erenumab in Japanese patients with migraine.
Suzuki K; Suzuki S; Shiina T; Haruyama Y; Kobayashi S; Shioda M; Hirata K
Heliyon; 2024 Feb; 10(4):e26568. PubMed ID: 38420497
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
[TBL] [Abstract][Full Text] [Related]
12. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
[TBL] [Abstract][Full Text] [Related]
13. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
Iannone LF; Burgalassi A; Vigani G; Tabasso G; De Cesaris F; Chiarugi A; Geppetti P
Cephalalgia; 2023 Apr; 43(4):3331024231160519. PubMed ID: 36918752
[TBL] [Abstract][Full Text] [Related]
14. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
Front Neurol; 2021; 12():788159. PubMed ID: 35069416
[No Abstract] [Full Text] [Related]
15. Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab.
Talbot J; Stuckey R; Wood N; Gordon A; Crossingham G; Weatherby S
Eur J Hosp Pharm; 2024 Jan; ():. PubMed ID: 38182276
[TBL] [Abstract][Full Text] [Related]
16. Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis.
Andreou AP; Fuccaro M; Hill B; Murphy M; Caponnetto V; Kilner R; Lambru G
J Headache Pain; 2022 Nov; 23(1):139. PubMed ID: 36333710
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study.
Varnado OJ; Brady BL; Zagar AJ; Robles YP; Hoyt M
Patient Prefer Adherence; 2024; 18():69-88. PubMed ID: 38223442
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study.
Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
Patient Prefer Adherence; 2022; 16():821-839. PubMed ID: 35378732
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
[TBL] [Abstract][Full Text] [Related]
20. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.
Torres-Ferrús M; Gallardo VJ; Alpuente A; Caronna E; Gine-Cipres E; Pozo-Rosich P
J Neurol; 2021 Oct; 268(10):3789-3798. PubMed ID: 33772636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]